Femasys Inc (FEMY) Peer Comparison

$2.67

$-0.11 (-3.96%)

As on 14-Sep-2026 16:00EDT

Market cap

$23 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

5.7

Div. Yield

0 %

Edit

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Market cap ($ Mln)	23	12,517	10,050	9,762	10,064
Revenue ($ Mln)	2	1,505	613	2,589	6,561
Net Profit ($ Mln)	-12.29	160.59	-188.05	222.40	-578.00
Net Margin (%)	-534.27	10.67	-30.68	8.59	-8.81
RoE (%)	-248.19	10.86	-28.10	3.04	-10.33
Price to Earnings	--	78.08	--	44.47	--
Price-To-Book	5.69	8.22	15.54	1.36	1.79

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Operating Revenue	2.30	1,504.87	612.84	2,589.30	6,561.10
Cost of Revenue	1.10	483.98	127.96	1,245.50	4,473.00
Gross Profit	1.42	942.44	393.22	1,343.60	2,139.40
Operating Expenses	18.77	833.56	565.37	1,108.90	2,373.70
Operating Profit (EBIT)	-17.57	187.34	-80.49	235.00	-285.60
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-11.76	203.83	-192.83	350.40	-472.00
Provision for Tax	0.52	43.24	-4.79	128.00	106.00
Profit after Tax (Net Income)	-12.29	160.59	-188.05	222.40	-578.00
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Shareholder's Funds	4.03	1,530.77	682.49	7,173.90	5,630.20
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	4.37	210.18	135.71	2,116.80	4,583.70
Current Liabilities	3.89	233.78	102.33	961.30	1,382.00
Total Liabilities	20.72	1,826.52	893.49	10,576.50	11,794.70

Assets ($ Mln)

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Non-Current Assets	3.96	630.60	404.74	7,231.50	9,133.70
Current Assets	8.33	1,344.12	515.78	3,020.50	2,462.20
Total Assets	20.72	1,826.52	893.49	10,576.50	11,794.70
Total Debt*	4.79	212.71	102.84	1,203.70	3,697.80
Net Current Assets	4.45	1,110.35	413.45	2,059.20	1,080.20

Cashflow ($ Mln)

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Cash From Operating Activities	-18.69	238.66	-46.34	532.20	623.80
Cash Flow from Investing Activities	-0.63	-404.59	-77.61	-189.70	-130.50
Cash from Financing Activities	25.14	26.53	11.89	-283.20	-409.40
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
ROCE (%)	-183.41	11.76	-22.53	8.98	-5.43
ROE (%)	-248.19	10.86	-28.10	3.04	-10.33
ROA (%)	-60.05	7.95	-18.00	2.02	-4.08
EBIT Margin (%)	-454.84	13.63	-30.58	-5.99	-4.47
Net Margin (%)	-534.27	10.67	-30.68	8.59	-8.81
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Revenue Growth (%)	21.86	17.55	41.55	1.37	-1.57
EBIT Growth (%)	45.54	17.49	-116.42	-131.06	-129.16
Net Profit Growth (%)	41.54	8.72	-102.66	-30.32	-184.08
EPS Growth (%)	64.30	8.12	-96.88	-29.66	-184.11
Book Value Growth (%)	15.02	17.33	-12.65	2.19	-9.82

Valuation Ratios

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Price / Earnings	-0.06	68.93	-34.59	--	-14.68
Price / Book Value	5.69	8.22	15.54	1.36	1.79
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-1.92	54.85	-69.66	18.24	108.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Debt to Equity	0.87	0.00	0.00	0.11	0.65
Short term debt to equity ratio	0.12	0.01	0.00	0.06	0.01
Current Ratio	2.14	5.75	5.04	3.14	1.78
Quick Ratio	0.55	3.86	4.46	2.33	1.18
Interest Coverage	-8.03	157.91	-38.31	8.18	-1.64

Operating Efficiency Ratios

	Femasys Inc (FEMY)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Avantor (AVTR)
Debtors to sales (%)	6.57	12.65	22.67	17.06	17.36
Asset Turnover	0.11	0.74	0.59	0.24	0.46
Receivable days	87.99	46.54	60.95	65.39	58.79
Inventory Days	1,839.35	331.92	193.84	221.09	64.13
Payable days	680.17	26.16	60.19	37.02	58.13
Cash Conversion Cycle	1,247.17	352.30	194.60	249.46	64.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly